Table 2.
In vitro activity of cefiderocol against selected clinical isolates by β-lactamase genotype in SIDERO-WT and SIDERO-CR
| Pathogen/β-lactamase genotypes (no. of isolates) | MIC90 (mg/L) [% susceptiblea] | ||||||
|---|---|---|---|---|---|---|---|
| FDC | FEP | CZA | C/T | CIP | CST | MEM | |
| Enterobacterales | |||||||
| KPC (644) [18, 45] | 2–4 [98.1] | > 64 [0] | 4 [96] | > 64 [0] | > 8 [5.3] | > 8 | > 64 [0] |
| NDM (162) [44, 45] | 8 [84–87.2] | > 64 | > 64 | > 64 | > 8 | 1 to > 8 | > 64 |
| VIM (174) [44, 45] | 4 [98.0] | > 64 | > 64 | > 64 | > 8 | 2 to > 8 | ≥ 64 |
| OXA-48 (168) [18, 45] | 4 [100] | > 64 [12.5] | 4 to > 64 [90.6] | > 64 [3.1] | > 8 [3.1] | > 8 [78.1] | ≥ 64 [0] |
| VIM (174) [44, 45] | 4 [98.0] | > 64 | > 64 | > 64 | > 8 | 2 to > 8 | ≥ 64 |
| P. aeruginosa | |||||||
| VIM (256) [44, 45] | 0.5–1 [100] | > 64 | > 64 | > 64 | > 8 to > 64 | 1–2 | > 8 to > 64 |
| IMP (16) [44] | 1 | > 64 | > 64 | > 64 | > 64 | 2 | > 8 |
| A. baumannii | |||||||
| OXA-23 (775) [18, 45] | 1–2 [92.2] | > 64.7 [1.7] | > 64 | > 64 | > 8 [0] | 1 to > 8 [79.6] | > 64 [0] |
| OXA-24 (237) [18, 45] | 1–8 [89.4] | > 64.7 [11.3] | > 64 | > 64 | > 8 [0] | 1 [96.8] | > 64 [0] |
| OXA-58 (14) [18] | 1 | > 64 [0] | > 64 | > 64 | > 8 [0] | 1 [92.9] | 16 [0] |
C/T ceftolozane-tazobactam, CIP ciprofloxacin, CST colistin, CZA ceftazidime-avibactam, FDC cefiderocol, FEP cefepime, MEM meropenem, MIC90 minimum inhibitory concentration required to inhibit 90% of isolates
aReported only where available